Long‐lived macrophage reprogramming drives spike protein‐mediated inflammasome activation in COVID‐19
Sebastian J. Theobald(University of Cologne), Jan Rybniker(University of Cologne), Henning Gruell(University of Cologne), Jakob J Malin(University of Cologne), Andromachi Pouikli(Max Planck Institute for Biology of Ageing), Florian Erger(University of Cologne), Jessica Gräb(University of Cologne), Christoph Kreer(University of Cologne), Janine Altmüller(University of Cologne), Alexander Simonis(University of Cologne), Hamid Kashkar(University of Cologne), Boris Böll(University Hospital Cologne), Peter Tessarz(Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases), Philipp Koehler(University of Cologne), Gerd Fätkenheuer(University of Cologne), Kanika Vanshylla(University of Cologne), Clara Lehmann(University of Cologne), Susanne Motameny(University of Cologne), Manuel Koch(University of Cologne), Julia Fischer(University of Cologne), Oliver A. Cornely(University of Cologne), Sandra Winter(University of Cologne), Friederike S. David(University of Cologne), Michael Hallek(University of Cologne), Peter Nürnberg(Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases), Marie‐Christine Albert(University of Cologne), Jason Chhen(University of Cologne), Isabelle Suárez(University of Cologne), Florian Klein(University of Cologne), Norma Jung(University of Cologne), Hannah S. Eisfeld(University of Cologne), Matthias Zehner(University of Cologne), Theodoros Georgomanolis(Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases)
Cited by 154
Related Papers
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
|New England Journal of Medicine|2007|1.8k
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
|The Lancet Infectious Diseases|2019|1.7k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k